For more than 30 years, scientists have studied how the myogenic determination gene number 1 (MYOD) protein binds DNA to modify the gene expression of muscle stem cells. MYOD is a transcription factor ...

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...

Midnight Rider' director Randall Miller argues that the DGA violated its constitution when it expelled him for life in 2022.

Paramount Global is putting its new leadership team in place, including Andy Gordon from Redbird and Kevin MacLellan, a ...

There are ways for the Bears to make a trade with Dallas for Micah Parsons but there's one slight issue that holds up any of that.

These 10 stocks could mint the next wave of millionaires › Ocugen (NASDAQ:OCGN), a biotechnology company developing gene therapies and regenerative medicine solutions for eye diseases, released its ...

Fortifying their bullpen for the stretch run, the New York Yankees acquired All-Star relievers David Bednar and Camilo Doval in separate deals as they made a flurry of moves Thursday just ahead of ...

The Texas Rangers are adding another reliever in the 11th hour of MLB’s trade deadline. Texas has finalized a deal with the ...

Get the 2025 update on the biotech companies Labiotech spotlighted in 2024 — who advanced, who stalled, and who surprised us.

Philly weekly roundup: Middle East deal for gene therapy startup; Saving the alleys; Medtech lessons from Omaha Plus, how to find an M&A advisor if you're looking to sell your company.

Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline.